ATE416769T1 - Neue verwendung von glutamat-antagonisten zur behandlung von krebs - Google Patents
Neue verwendung von glutamat-antagonisten zur behandlung von krebsInfo
- Publication number
- ATE416769T1 ATE416769T1 AT05012871T AT05012871T ATE416769T1 AT E416769 T1 ATE416769 T1 AT E416769T1 AT 05012871 T AT05012871 T AT 05012871T AT 05012871 T AT05012871 T AT 05012871T AT E416769 T1 ATE416769 T1 AT E416769T1
- Authority
- AT
- Austria
- Prior art keywords
- glutamate
- new use
- cancer
- treat cancer
- glutamate antagonists
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 229940122459 Glutamate antagonist Drugs 0.000 title abstract 2
- 239000003194 amino acid receptor blocking agent Substances 0.000 title abstract 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- 229930195712 glutamate Natural products 0.000 abstract 2
- 102000003678 AMPA Receptors Human genes 0.000 abstract 1
- 108090000078 AMPA Receptors Proteins 0.000 abstract 1
- 229940098747 AMPA receptor antagonist Drugs 0.000 abstract 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical class CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 abstract 1
- 229940127492 Kainate Receptor Antagonists Drugs 0.000 abstract 1
- 108010069902 Kainic Acid Receptors Chemical class 0.000 abstract 1
- 102000000079 Kainic Acid Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Chemical class 0.000 abstract 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98250380A EP1002535A1 (de) | 1998-10-28 | 1998-10-28 | Neue Verwendung von Glutamat-Antagonisten zur Behandlung von Krebs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE416769T1 true ATE416769T1 (de) | 2008-12-15 |
Family
ID=8234602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05012871T ATE416769T1 (de) | 1998-10-28 | 1999-10-22 | Neue verwendung von glutamat-antagonisten zur behandlung von krebs |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6797692B1 (de) |
| EP (4) | EP1002535A1 (de) |
| JP (1) | JP2002528415A (de) |
| AT (1) | ATE416769T1 (de) |
| AU (1) | AU6475099A (de) |
| DE (1) | DE69940080D1 (de) |
| WO (1) | WO2000024395A1 (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE285769T1 (de) * | 1998-12-04 | 2005-01-15 | Neurosearch As | Verwendung von isatinderivaten als ionenkanalaktivierende mittel |
| EP1736468A3 (de) | 2000-01-24 | 2007-01-03 | NeuroSearch A/S | Isatinderivate mit neurotropischer Aktivität geeignet zur Behandlung von NGF-bedingten Krankheiten |
| EP1157682A1 (de) * | 2000-05-25 | 2001-11-28 | Cilag AG | Blisterpackung für Topiramattabletten |
| DE10112926B4 (de) * | 2001-03-13 | 2005-11-10 | Schebo Biotech Ag | Verwendung von Aminooxyacetat zur Tumorbehandlung |
| CA2442478C (en) | 2001-04-02 | 2010-02-02 | Mark F. Bear | Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation |
| US6916821B2 (en) | 2001-04-02 | 2005-07-12 | Brown University | Methods of treating disorders with Group I mGluR antagonists |
| KR100537436B1 (ko) * | 2001-05-31 | 2005-12-21 | 김익수 | 복어 알 추출액을 함유하는 항암 치료용 약학 조성물 |
| CA2457011C (en) | 2001-08-20 | 2012-04-24 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
| AU2003220825A1 (en) | 2002-03-29 | 2003-10-13 | Yamanouchi Pharmaceutical Co., Ltd. | Remedy for glioblastoma |
| AU2003272175A1 (en) * | 2002-10-21 | 2004-05-04 | Aprea Ab | Reactivation of wild type p53 in human tumour cells by a low molecular weight compound |
| WO2004050081A1 (en) * | 2002-12-02 | 2004-06-17 | University Of Florida | Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases |
| KR100581344B1 (ko) * | 2003-05-02 | 2006-05-23 | 주식회사디엔에이링크 | 텔로머라제 활성 억제용 조성물 |
| US8017622B2 (en) | 2003-05-16 | 2011-09-13 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| US8835473B2 (en) * | 2004-04-16 | 2014-09-16 | Rutgers, The State University Of New Jersey | Methods and compositions for treating cancer |
| FR2872358B1 (fr) * | 2004-06-23 | 2006-09-29 | Comsis Sa | Decodeur numerique pour systeme de transmission numerique sans fil utilisant un code spatio-temporel lineaire |
| GB0416730D0 (en) | 2004-07-27 | 2004-09-01 | Novartis Ag | Organic compounds |
| EP1858501A1 (de) * | 2005-03-07 | 2007-11-28 | Michael Hermanussen | Nmda-rezeptor-antagonisten bei der medizinischen intervention von stoffwechselerkrankungen |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| US7842468B2 (en) | 2005-04-19 | 2010-11-30 | Trustees Of Dartmouth College | Methods for diagnosing and treating neuroendocrine cancer |
| US9694072B2 (en) | 2005-04-19 | 2017-07-04 | Trustees Of Dartmouth College | Methods for diagnosing and treating neuroendocrine cancer |
| US8592168B2 (en) * | 2005-04-19 | 2013-11-26 | Trustees Of Darmouth College | Methods for diagnosing and treating neuroendocrine cancer |
| US8415109B2 (en) * | 2005-04-19 | 2013-04-09 | Trustees Of Dartmouth College | Methods for diagnosing and treating neuroendocrine cancer |
| WO2007017652A2 (en) * | 2005-08-10 | 2007-02-15 | Astrazeneca Ab | Arylakylamines for the treatment of cancer |
| US7732447B2 (en) | 2006-06-22 | 2010-06-08 | Cephalon, Inc. | Fused [d]pyridazin-7-ones |
| US8889950B2 (en) | 2006-07-28 | 2014-11-18 | The George Washington University | Repression of AtGLR3.2 increases plant biomass |
| CA2606658A1 (en) * | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| FR2910811B1 (fr) * | 2007-01-03 | 2009-07-10 | Ass Pour Le Dev De La Biothera | Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments |
| GB0713116D0 (en) * | 2007-07-06 | 2007-08-15 | Therapeutics Ltd E | Treatment of melanoma |
| WO2009016486A2 (en) * | 2007-08-02 | 2009-02-05 | Compugen, Ltd | Use of nmda receptor antagonists for treatment of urologic tumors |
| DE102007047737A1 (de) | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| US20090210967A1 (en) * | 2007-10-17 | 2009-08-20 | Turano Frank J | Glutamate Receptors as Regulators of Carbon Transport, Mobilization, Distribution, Reallocation, and Partitioning in Higher Plants |
| GB0722274D0 (en) * | 2007-11-13 | 2007-12-27 | Ludwig Inst Cancer Res | New therapeutic method |
| KR101220455B1 (ko) | 2008-03-12 | 2013-01-31 | 김현호 | 산왕거미 추출물을 포함하는 면역세포증가용 약학적 조성물 |
| WO2009148623A2 (en) | 2008-06-05 | 2009-12-10 | Stc.Unm | Methods and related compositions for the treatment of cancer |
| AR072434A1 (es) | 2008-07-03 | 2010-08-25 | Monsanto Technology Llc | Combinaciones de agentes tensioactivos de sacaridos derivatizados y agentes tensioactivos de oxido de eteramina como adyuvantes de herbicidas |
| CN101569617A (zh) * | 2009-06-11 | 2009-11-04 | 辽宁利锋科技开发有限公司 | 具有金刚烷结构药物及其衍生物和类似物抗肿瘤新适应症的应用 |
| JP5643818B2 (ja) * | 2009-06-18 | 2014-12-17 | ファイザー・インク | Ｋａｔｉｉ阻害剤としての二環式および三環式化合物 |
| WO2011006170A2 (en) * | 2009-07-10 | 2011-01-13 | Microbial-Vac Systems, Inc. | System and method for cleaning contaminant collection equipment |
| GB0915877D0 (en) * | 2009-09-10 | 2009-10-14 | E Therapeutics Plc | Cancer cell apoptosis |
| DE102009049211A1 (de) | 2009-10-13 | 2011-04-28 | Merck Patent Gmbh | Sulfoxide |
| US9526911B1 (en) * | 2010-04-27 | 2016-12-27 | Lazure Scientific, Inc. | Immune mediated cancer cell destruction, systems and methods |
| JP5562716B2 (ja) * | 2010-05-12 | 2014-07-30 | 花王株式会社 | 電位依存性カチオンチャネル抑制剤 |
| US10864271B2 (en) | 2012-02-15 | 2020-12-15 | Rutgers, The State University Of New Jersey | Combination therapy using riluzole to enhance tumor sensitivity to ionizing radiation |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| WO2014152207A1 (en) | 2013-03-15 | 2014-09-25 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US11377452B2 (en) | 2017-01-16 | 2022-07-05 | Drexel University | Glutamate transporter activators and methods using same |
| EP3700527A4 (de) * | 2017-10-25 | 2021-03-10 | Children's Medical Center Corporation | Papd5-inhibitoren und verfahren zur verwendung davon |
| JP2019151621A (ja) * | 2018-02-28 | 2019-09-12 | 学校法人藤田学園 | Ｋａｔ阻害活性を有する化合物を含有するがん治療用組成物 |
| EP3829567A4 (de) * | 2018-07-27 | 2022-05-04 | With Great Power, LLC | Klinische verfahren und pharmazeutische zusammensetzungen mit ampa-rezeptor-antagonisten zur behandlung von glioblastom und anderen karzinomen |
| EP3959197A4 (de) | 2019-04-24 | 2022-10-12 | Children's Medical Center Corporation | Papd5-inhibitoren und verfahren zur verwendung davon |
| CN114341125A (zh) * | 2019-05-02 | 2022-04-12 | 星座制药公司 | Trex1调节剂 |
| WO2021011876A2 (en) * | 2019-07-18 | 2021-01-21 | The Wistar Institute Of Anatomy And Biology | Modulators of excitatory amino acid transporters and methods using same |
| WO2022197767A1 (en) * | 2021-03-17 | 2022-09-22 | Memorial Sloan-Kettering Cancer Center | Methods for improving survival in lung cancer patients via ketamine oncoprotection |
| JP2023043944A (ja) * | 2021-09-17 | 2023-03-30 | 国立大学法人金沢大学 | 腫瘍治療用医薬組成物 |
| CN114364242B (zh) * | 2021-12-18 | 2025-04-29 | 中北大学 | 基于锌-铁配合物衍生的多孔复合吸波剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| GB8810173D0 (en) * | 1988-04-29 | 1988-06-02 | Norsk Hydro As | Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer |
| US5506231A (en) * | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| US4994467A (en) * | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| US5039528A (en) * | 1989-12-11 | 1991-08-13 | Olney John W | EAA antagonists as anti-emetic drugs |
| US5958930A (en) * | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
| US5710179A (en) * | 1995-04-05 | 1998-01-20 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Antitumor agent |
| TW427904B (en) * | 1995-12-07 | 2001-04-01 | American Home Prod | Neuroprotective agents |
| US6046180A (en) * | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
-
1998
- 1998-10-28 EP EP98250380A patent/EP1002535A1/de not_active Withdrawn
-
1999
- 1999-10-22 EP EP05012872A patent/EP1649857A3/de not_active Withdrawn
- 1999-10-22 AT AT05012871T patent/ATE416769T1/de not_active IP Right Cessation
- 1999-10-22 EP EP05012871A patent/EP1586321B1/de not_active Expired - Lifetime
- 1999-10-22 EP EP99952622A patent/EP1124553A1/de not_active Withdrawn
- 1999-10-22 US US09/830,354 patent/US6797692B1/en not_active Expired - Fee Related
- 1999-10-22 JP JP2000578005A patent/JP2002528415A/ja active Pending
- 1999-10-22 AU AU64750/99A patent/AU6475099A/en not_active Abandoned
- 1999-10-22 DE DE69940080T patent/DE69940080D1/de not_active Expired - Lifetime
- 1999-10-22 WO PCT/EP1999/008004 patent/WO2000024395A1/en not_active Ceased
-
2004
- 2004-08-06 US US10/912,159 patent/US7247610B2/en not_active Expired - Fee Related
- 2004-08-06 US US10/912,175 patent/US20050054650A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050054619A1 (en) | 2005-03-10 |
| WO2000024395A1 (en) | 2000-05-04 |
| EP1586321B1 (de) | 2008-12-10 |
| EP1649857A3 (de) | 2007-03-28 |
| EP1124553A1 (de) | 2001-08-22 |
| US6797692B1 (en) | 2004-09-28 |
| EP1649857A2 (de) | 2006-04-26 |
| US7247610B2 (en) | 2007-07-24 |
| EP1002535A1 (de) | 2000-05-24 |
| US20050054650A1 (en) | 2005-03-10 |
| EP1586321A1 (de) | 2005-10-19 |
| JP2002528415A (ja) | 2002-09-03 |
| AU6475099A (en) | 2000-05-15 |
| DE69940080D1 (de) | 2009-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69940080D1 (de) | Neue Verwendung von Glutamat-Antagonisten zur Behandlung von Krebs | |
| DE69918296D1 (de) | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen | |
| DK0740650T3 (da) | Codrugs som metode til styret transport af lægemiddel | |
| WO2000001376A3 (en) | Pharmaceutical compositions and their uses for treatment of demyelinating disorders | |
| DE69507029D1 (de) | Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten | |
| DE60321929D1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| UA41297C2 (uk) | Похідні індолу, фармацевтична композиція і спосіб лікування | |
| DE60123381D1 (de) | Neue dosisformen von substituierten benzimidazolen und verfahren zur deren verwendung | |
| EA200300354A1 (ru) | Хинолиноновые производные в качестве ингибиторов тирозинкиназы | |
| PT1119543E (pt) | N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y | |
| HRP20030071B1 (hr) | Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| RU98105512A (ru) | Применение производных пиримидина для профилактики рака отдельно или в комбинации с другими терапевтическими мероприятиями | |
| BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
| BR0314353A (pt) | Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio | |
| DE69940951D1 (de) | Nd wachstumshemmende mittel | |
| BR9507073A (pt) | Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto | |
| AU9042201A (en) | 1-azabicyclo(2.2.2)octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors | |
| DE60233433D1 (de) | PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN | |
| ATE230993T1 (de) | Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| EE03526B1 (et) | Leukotrieen-antagonistliku toimega bensopüraanderivaadid, nende valmistamismeetod ja kasutamine | |
| DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung | |
| DE60143078D1 (de) | Pax2 zur behandlung von nierenkrankheiten | |
| ATE530184T1 (de) | Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |